Ketamine after the hype: What are we actually treating?

ObjectiveKetamine has transformed depression research by demonstrating rapid antidepressant effects through mechanisms beyond monoaminergic neurotransmission. This perspective argues that the ketamine story also provides an opportunity to re-examine broader conceptual and methodological challenges in depression research, including the definition of treatment-resistant depression, patient selection, recruitment strategies, outcome measures and the interpretation of clinical trials.ConclusionsRather than questioning whether ketamine works, this perspective asks whether depression research generates evidence that meaningfully informs clinical decisions. Differences in patient populations, recruitment strategies, expectations and outcome measures may substantially shape treatment estimates. More precise clinical characterisation and greater emphasis on patient-important outcomes may help bridge the gap between efficacy demonstrated in trials and the choice of treatment for individual patients.

Authors

Institutions

Publication Details

Journal
Australasian Psychiatry
Published
2026-11-16
DOI
https://doi.org/10.1177/10398562261508726
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ketamine after the hype: What are we actually treating?

Pouya Movahed
Australasian Psychiatry
Treatment of Major Depression
article

Ketamine after the hype: What are we actually treating?

Pouya Movahed
article en

Abstract

ObjectiveKetamine has transformed depression research by demonstrating rapid antidepressant effects through mechanisms beyond monoaminergic neurotransmission. This perspective argues that the ketamine story also provides an opportunity to re-examine broader conceptual and methodological challenges in depression research, including the definition of treatment-resistant depression, patient selection, recruitment strategies, outcome measures and the interpretation of clinical trials.ConclusionsRather than questioning whether ketamine works, this perspective asks whether depression research generates evidence that meaningfully informs clinical decisions. Differences in patient populations, recruitment strategies, expectations and outcome measures may substantially shape treatment estimates. More precise clinical characterisation and greater emphasis on patient-important outcomes may help bridge the gap between efficacy demonstrated in trials and the choice of treatment for individual patients.

Australasian Psychiatry
Lund University (SE)
Treatment of Major Depression
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon